RANCHO CORDOVA, Calif., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL) (the “Company”), an autologous cell-based regenerative medicine company, today reported financial results for the second quarter of fiscal 2016 and provided an update to investors. The update included details of the closing of the previously announced $15 million strategic investment made in the Company by the Boyalife Group (“Boyalife”), a discussion of the scope of Boyalife’s healthcare-related business interests and an update on the status of Cesca’s FDA approved Phase III pivotal trial for the treatment of “no-option” patients with critical limb ischemia (CLI).
The Boyalife Financing
On February 3, 2016, the Company announced that Boyalife had agreed to invest $15.0 million in the Company (the “Boyalife Financing”), enabling the Company to repay currently outstanding senior secured convertible debentures, retire associated Series B Warrants and fund the Company’s ongoing operations and strategic initiatives.
Today, the Company reported that the Boyalife Financing had closed, that the Company had received aggregate cash proceeds of $15.0 million and that it had paid off the outstanding debentures held by its existing senior secured lender. The Company also reported that, following receipt of the payment, the lender exercised Series B warrants under the cashless exercise provision for 2.5 million shares of common stock. All remaining and unexercised Series B Warrants have since been surrendered to the Company and terminated.
“I am delighted that this transaction has now closed,” commented Robin C. Stracey, Cesca’s CEO. “In Boyalife we have a well-funded and strategically-oriented investment partner that sees great value-creation potential in our clinical programs and is committed to our success. We have only just begun to explore the potential synergies and opportunities for accelerated growth that may result from their involvement,” he added.
Second Quarter Fiscal 2016 Financial Results
The Company reported that net revenues for the three months ended December 31, 2015 were in line with expectations at $3.3 million, compared to $4.6 million for the three months ended December 31, 2014. The decrease was primarily due to the fact that the Company sold three BioArchive systems in the three months ended December 31, 2014 but did not ship any in the current quarter. Revenues from the Res-Q product line also decreased following notification by the Company to its US distributor that it would not allow further automatic extensions, thereby terminating the distribution agreement effective March 31, 2016.
Gross profit was $1.0 million or 31% of net revenues for the three months ended December 31, 2015, compared to $1.5 million or 33% for the corresponding fiscal 2015 period. Gross profit margin was broadly consistent with prior year despite the decrease in revenues, primarily because of lower personnel overhead costs attributable to the Company’s September 2015 restructuring initiative.
Operating expenses for the quarter ended December 31, 2015 were $3.0 million, compared to $5.9 million for the same period in the prior year. The expense reduction was primarily due to lower legal fees mainly associated with settling certain patent litigation cases in fiscal 2015, a decrease in stock based compensation and lower personnel costs due to the September 2015 restructuring initiative.
Net loss for the quarter ended December 31, 2015 was $0.6 million, compared to $4.4 million for the same prior year period. The reduction in net loss of $3.8 million was attributable to the decrease in operating expenses as already described and a non-cash benefit associated with the fair value change of derivatives instruments, partially offset by a non-cash loss on cashless exercise of warrants. The derivative instruments are associated with the senior secured convertible debentures and warrants sold during the first fiscal quarter and the benefit is the result of a lower stock price at the end of the current quarter.
Adjusted EBITDA loss was $1.7 million for the quarter ended December 31, 2015 compared to $3.6 million for the same period in the prior year. The decrease in the adjusted EBITDA loss was the result of the decreased loss from operations as already described.
Cash and cash equivalents were $2.9 million as of December 31, 2015.
In addition to the results reported in accordance with U.S. GAAP, Cesca also uses a non-GAAP measure, adjusted EBITDA, to evaluate operating performance and to facilitate comparisons with historical results and trends. This financial measure is not a measure of financial performance under U.S. GAAP and should not be considered in isolation or as a substitute for loss as a measure of performance. The calculation of this non-GAAP measure may not be comparable to similarly titled measures used by other companies.
Conference Call and Webcast
Management will hold a conference call today at 2:00pm Pacific (5:00pm Eastern) to update investors and review the second quarter fiscal 2016 financial results.
Conference call details:
To listen to the audio webcast of the call during or after the event, please visit http://cescatherapeutics.com/investors/webcasts-calls/
An audio replay of the conference call will be available beginning approximately two hours after completion of the call for the following five business days.
To access the replay:
|Access number (U.S.):||1-877-344-7529|
|Access number (Internationally)||1-412-317-0088|
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. These include:
The SurgWerks™ with VXP Platform - proprietary, indication-specific stem cell therapy kits and associated devices, for use at the point-of-care in treating vascular and orthopedic diseases.
The CellWerksTM Platform - a proprietary stem cell laboratory system for processing target cells used in the treatments of oncological and hematological disorders.
The AutoXpress® Platform (AXP®) - a proprietary automated device with companion sterile blood processing disposables for harvesting stem cells from cord blood.
The MarrowXpress® Platform (MXP®), a derivative product of the AXP and its accompanying disposable bag set, for the isolation and concentration of stem cells from bone marrow.
The BioArchive® System, an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell specimens for future use in approved regenerative medicine procedures.
Forward Looking Statement
Some of the statements contained in this letter are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or our future performance and include statements about the timing and structure of the proposed financing, repayment of our existing debt and termination of the remaining Series B warrants and the future relationship between the Company and Boyalife Group, as well as other statements that can be identified by the use of the forward looking terminology such as “may,” “will,” or similar terms, variations of such terms, or the negative of such terms. These forward-looking statements are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
|Cesca Therapeutics Inc.|
|Condensed Consolidated Balance Sheets|
|(in thousands)||December 31, |
|June 30, |
|Cash and cash equivalents||$||2,942||$||3,357|
|Accounts receivable, net||3,467||5,133|
|Prepaid expenses and other current assets||336||163|
|Total current assets||10,731||13,251|
|Intangible assets, net||21,045||21,295|
|Other current liabilities||2,966||2,867|
|Total current liabilities||7,390||7,946|
|Cesca Therapeutics Inc.|
|Condensed Consolidated Statements of Operations|
|(in thousands, except share and per share amounts)||Three Months Ended |
|Six Months Ended |
|Cost of revenues||2,266||3,102||4,722||5,571|
|Sales and marketing||527||720||1,159||1,528|
|Research and development||646||1,542||1,743||3,019|
|General and administrative||1,823||3,632||4,375||5,820|
|Total operating expenses||2,996||5,894||7,277||10,367|
|Loss from operations||(1,968||)||(4,353||)||(5,882||)||(7,640||)|
|Fair value change of derivative instruments||2,180||--||3,606||--|
|Registration rights liquidated damages||(220||)||--||(1,100||)||--|
|Loss on cashless exercise of warrants||(564||)||--||(564||)||--|
|Other expense, net||(52||)||(18||)||(81||)||(27||)|
|Other comprehensive income:|
|Foreign currency translation adjustments||1||(37||)||(24||)||(69||)|
|Per share data:|
|Basic and diluted net loss per |
|Shares used in computing per share data||41,384,666||40,303,628||40,968,454||40,289,170|
|Cesca Therapeutics Inc.|
|Condensed Consolidated Statements of Cash Flows|
|(in thousands)||Six Months Ended|
|Cash flows from operating activities:|
|Adjustments to reconcile net loss to net cash used|
in operating activities:
|Depreciation and amortization||659||667|
|Stock based compensation expense||304||676|
|Amortization of debt discount and issue costs||62||--|
|Change in fair value of derivative||(3,606||)||--|
|Loss on cashless exercise of warrants||564||--|
|Net change in operating assets and liabilities:|
|Accounts receivable, net||1,634||114|
|Prepaid expenses and other current assets||(299||)||(83||)|
|Accrued payroll and related expenses||(243||)||361|
|Net cash used in operating activities||(4,494||)||(5,869||)|
|Cash flows from investing activities:|
|Net cash used in investing activities||(602||)||(455||)|
|Cash flows from financing activities:|
|Proceeds from convertible debentures, net||4,720||--|
|Payments on capital lease obligations||(27||)||(16||)|
|Repurchase of common stock||(5||)||(80||)|
|Net cash provided by (used in) financing activities||4,688||(96||)|
|Effects of foreign currency rate changes on cash and cash equivalents||(7||)||(34||)|
|Net decrease in cash and cash equivalents||(415||)||(6,454||)|
|Cash and cash equivalents at beginning of period||3,357||14,811|
|Cash and cash equivalents at end of period||$||2,942||$||8,357|
|Cesca Therapeutics Inc.|
|(in thousands)||Three Months Ended |
|Six Months Ended|
|Loss from operations||$||(1,968||)||$||(4,353||)||$||(5,882||)||$||(7,640||)|
|Depreciation and amortization||294||345||659||667|
|Stock-based compensation expense||(39||)||392||304||676|
|Adjusted EBITDA loss||$||(1,713||)||$||(3,616||)||$||(4,919||)||$||(6,297||)|
Contact: Cesca Therapeutics Inc. http://www.cescatherapeutics.com Investor Contact: Kirin Smith, PCG Advisory Group + 1-646-863-6519, or email@example.com Media Contact: Sean Leous, PCG Advisory Group +1-646-863-8998
Source:Cesca Therapeutics Inc.